Abstract Observations that dopaminergic antagonists are beneficial in bipolar disorder and that dopaminergic agonists can produce mania suggest that bipolar disorder involves excessive dopaminergic transmission. Thus, mood stabilizers used to treat the disease might act in part by downregulating dopaminergic transmission. In agreement, we reported that dopamine D 2 -like receptor mediated signaling involving arachidonic acid (AA, 20:4n-6) was downregulated in rats chronically treated with lithium. To see whether chronic carbamazepine, another mood stabilizer, did this as well, we injected i.p. saline or the D 2 -like receptor agonist, quinpirole (1 mg/kg), into unanesthetized rats that had been pretreated for 30 days with i.p. carbamazepine (25 mg/kg/day) or vehicle, and used quantitative autoradiography to measure regional brain incorporation coefficients (k*) for AA, markers of signaling. We also measured brain prostaglandin E 2 (PGE 2 ), an AA metabolite. In vehicle-treated rats, quinpirole compared with saline significantly increased k* for AA in 35 of 82 brain regions examined, as well as brain PGE 2 concentration. Affected regions belong to dopaminergic circuits and have high D 2 -like receptor densities. Chronic carbamazepine pretreatment prevented the quinpirole-induced increments in k* and in PGE 2 . These findings are consistent with the hypothesis that effective mood stabilizers generally downregulate brain AA signaling via D 2 -like receptors, and that this signaling is upregulated in bipolar disorder.
Introduction
Lithium, valproic acid and carbamazepine (5H-dibenz[b,f]azepine-5-carboxamide) (CBZ) are used to treat mania in bipolar disorder, but whether they have a common mechanism of action is not agreed on [3] . One possibility is that these agents correct a neurotransmission imbalance that contributes to bipolar symptoms. Clinical evidence suggests that excessive or abnormal dopaminergic signaling contributes to this neurotransmission imbalance [13, 28, 31] . Thus, drugs that inhibit dopaminergic transmission (e.g., haloperidol) have an antimanic action in bipolar disorder [20] , whereas drugs that stimulate dopamine synthesis (levodopa), bind to dopamine receptors (bromocriptine), or reduce dopamine reuptake (amphetamine), often precipitate mania [1, 40] .
Brain signal transduction mediated by dopaminergic D 2 -like (D 2 , D 3 and D 4 ) receptors can be coupled to the activation of Ca 2+ -dependent cytosolic phospholipase A 2 (cPLA 2 ), to selectively release arachidonic acid (AA, 20:4n-6), from the stereospecifically numbered (sn)-2 position of membrane phospholipid [53] . The signaling process can be imaged in unanesthetized rats by injecting intravenously [1- 14 C]AA and measuring tracer AA uptake into brain using quantitative autoradiography. Regional brain AA incorporation coefficients k* (brain radioactivity/integrated plasma radioactivity) are calculated and, if multiplied by unlabeled unesterified plasma AA concentrations, are converted to regional incorporation rates J in that represent regional brain AA consumption. Both k* and J in are independent of changes in cerebral blood flow [44, 46] . Increments in k* caused by drug reflect the quantity of unesterified AA released and then metabolized to eicosanoids (e.g. prostaglandin E 2 (PGE 2 ), thromboxane B 2 (TXB 2 )) and other products [9, 10] . Unesterified AA as well as its eicosanoid metabolites are bioactive and can influence many physiological processes, including membrane excitability, gene transcription, apoptosis, sleep, brain blood flow and behavior [49] .
Consistent with inhibition of dopaminergic receptormediated signaling by mood stabilizers, we reported that chronic LiCl feeding, sufficient to produce therapeutically relevant plasma and brain lithium concentrations, blocked k* signals caused by administration of the D 2 -like receptor agonist, quinpirole, to unanesthetized rats [5] . In control animals fed a LiCl-free diet, quinpirole-induced increases in k* are robust and widespread in brain regions within dopaminergic circuits, and can be blocked by pre-treatment with the D 2 -like receptor antagonists, butaclamol or raclopride [16, 29] . In addition to LiCl, chronic CBZ has been reported to attenuate dopamine function in rats, suggesting that normalization of a dysfunctional dopamine neurotransmission may underlie CBZ effects in bipolar disorder [2, 4, 35, 38] .
In the present study, we determined if chronic CBZ administration, like chronic LiCl, would block the k* increments in response to quinpirole, and would influence brain PGE 2 or TXB 2 concentrations at rest or following drug. We measured these global brain concentrations, as well as k* for AA in 82 brain regions, in unanesthetized rats that had been treated daily for 30 days with i.p. vehicle or CBZ 25 mg/kg, then administered saline (control) or quinpirole (1.0 mg/kg i.v.). The CBZ regimen produces a plasma CBZ concentration of 54 lM, at the high end found in CBZ-treated bipolar patients (51 lM), and decreases AA turnover in brain phospholipids and the brain PGE 2 concentration [2, 11, 18, 27] . The quinpirole dose increases k* for AA significantly in brain dopaminergic circuits [5, 15] .
Experimental Procedures

Animals and Diets
The study was approved by the National Institutes of Health (NIH) Animal Care and Use Committee in accordance with NIH Guidelines on the Care and Use of Laboratory Animals. Two-month-old male Fischer CDF (F-344)/CrlBR rats (Charles River Laboratories, Wilmington, MA, USA) were acclimatized for 1 week in an animal facility in which temperature, humidity and light cycle were regulated, and had ad libitum access to food (NIH-31 diet, Zeigler, Gardners, PA, USA) and water. The diet contained (as percent of total fatty acids): 20.1% saturated, 22.5% monounsaturated, 47.9% linoleic, 5.1% a-linolenic, 0.02% AA, 2.0% eicosapentaenoic, and 2.3% docosahexaenoic acid.
Drugs [1-
14 C]AA in ethanol (53 mCi/mmol, [98% pure, Moravek Biochemicals, Brea, CA, USA) was evaporated and resuspended in HEPES buffer, pH 7.4, containing 50 mg/ ml fatty acid-free bovine serum albumin (Sigma-Aldrich, St Louis, MO, USA). CBZ-treated rats received 25 mg/kg intraperitoneally once daily for 30 days (Sigma-Aldrich). The CBZ was dissolved in a 50:50 (v/v) dimethyl sulfoxide (DMSO, C99.9% Sigma-Aldrich): saline (0.9% NaCl, Hospira Inc., Lake Forest, IL, USA) mixture and kept at 37°C as described previously [2, 11, 27] . A control group received the same volume of DMSO:saline (vehicle) under parallel conditions. The acute 1 mg/kg i.v. dose of (-)-quinpirole hydrochloride (Sigma-Aldrich), a selective D 2 -like dopamine receptor agonist [47] , was chosen because it does not cause convulsions but produces widespread significant increments in k* for AA in the brain of unanesthetized rats that can be blocked by D 2 -like receptor antagonists [5, 15] .
Surgical Procedures and Tracer Infusion
On the morning of day 30 of chronic treatment, a rat was injected with the last CBZ or vehicle dose and then anesthetized with 2-3% halothane in O 2 . Polyethylene catheters (PE 50) were inserted into the right femoral artery and vein as described previously [5] . The wound was closed with surgical clips and the rat was wrapped loosely, with its upper body remaining free, in a fast-setting plaster cast taped to a wooden block. Surgery lasted 20-25 min. The rat was allowed to recover from anesthesia for 4 h in an environment maintained at 25°C. Body temperature was maintained at 36.4-37.1°C using a feedback-heating device and rectal thermometer. Arterial blood pressure and heart rate were measured with a blood pressure recorder (CyQ 103/302; Cybersense, Inc., Nicholasville, KY, USA). Arterial blood pH, pO 2 and pCO 2 were measured with a blood gas analyzer (Model 248, Bayer Health Care, Norwood, MA, USA).
One minute after an i.v. injection of quinpirole or saline, [1- 14 C]AA (170 lCi/kg) in 2 ml was infused into the femoral vein for 5 min at a rate of 400 ll/min, using an infusion pump (Harvard Apparatus Model 22, Natick, MA, USA). Twenty min after beginning tracer infusion, the rat was killed with an overdose of Nembutal Ò (100 mg/kg, i.v.) and decapitated. The brain was removed (\30 s), frozen in 2-methylbutane maintained at -40°C with dry ice, and stored at -80°C until sectioned.
Chemical Analysis
Thirteen arterial blood samples were collected before, during and after [1- 14 C]AA infusion, and were centrifuged immediately (30 s at 18,000g). Total lipids were extracted from 30 ll of plasma with 3 ml chloroform:methanol (2:1, by vol) and 1.5 ml 0.1 M KCl using the Folch procedure [26] . Radioactivity was determined at an efficiency of 88% in 100 ll of the lower organic phase by liquid scintillation counting. As reported, following 5 min [1- 14 C]AA infusion, 98% of total plasma radioactivity was radiolabeled AA [11] . Concentrations of unesterified fatty acids were determined in 100-150 ll of the frozen arterial plasma. Total lipids were extracted by the method of Folch et al. [26] , and were separated by thin layer chromatography on silica gel 60 plates (Whatman, Clifton, NJ, USA) using the solvent system, heptane:diethylether:glacial acetic acid (60:40:3, by vol). Unesterified fatty acids were scraped from the plate and methylated with 1% H 2 SO 4 in anhydrous methanol for 3 h at 70°C. Fatty acid methyl esters were then separated and quantified by gas chromatography using an internal standard, heptadecanoic acid (17:0) [11] .
Quantitative Autoradiography
Frozen brains were cut in serial 20-lm thick coronal sections in a cryostat at -20°C. Sections were placed for 5 weeks with calibrated [
14 C]methylmethacrylate standards on Kodak Ektascan C/RA film (Eastman Kodak Company, Rochester, NY, USA). Brain regions from autoradiographs were identified from a stereotaxic rat brain atlas [39] , and were sampled in both hemispheres. The average of bilateral measurements for each region from three consecutive brain sections was used to calculate regional radioactivity (nCi/g of brain) by digital quantitative densitometry, using a Macintosh computer and the public domain NIH Image program 1.62 (developed at the US National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/). Regional incorporation coefficients k* (ml plasma/s/g brain) of AA were calculated as [46] ,
c Ã plasma equals plasma radioactivity determined by scintillation counting (nCi/ml), c Ã brain equals brain radioactivity (nCi/g of brain), and t equals time (min) after beginning of [1- 14 C]AA infusion.
Rates of incorporation of unesterified AA from plasma into brain phospholipids, J in (fmol/s/g) were calculated as,
where c plasma is the plasma concentration of unlabeled unesterified AA (nmol/ml).
Brain PGE 2 and TXB 2 Concentrations
In separate experiments, on the morning of day 30, rats received the last injection of CBZ or vehicle, and 3 h and 30 min later were injected i.v. with quinpirole (1 mg/kg) or saline. Twenty-one minutes later, they were anesthetized with Nembutal Ò (50 mg/kg, i.p.) and subjected to highenergy head-focused microwave irradiation (5.5 kW, 3.8 s; Cober Electronics, Stamford, CT, USA) to stop post-mortem changes, such as formation of prostaglandins and fatty acid release from phospholipid [41] . Half-brains were weighed, homogenized with 18 volumes of hexane:isopropanol (3:2, by vol) using a glass Tenbroeck homogenizer and the homogenate was centrifuged for 5 min at 800g. Tissue residues were rinsed with 3 9 2 vol of the same solvent. The resultant lipid extract was concentrated to dryness under nitrogen and resuspended in the enzyme immunoassay buffer provided with a polyclonal PGE 2 or TXB 2 kit (Oxford Biochemical Research, Oxford, MI, USA).
Statistical Analyses
An unpaired two-tailed t-test was used to compare mean physiological parameters in CBZ-and vehicle-treated rats, using GraphPad Prism version 4.0b (GraphPad Software, San Diego, CA, www.graphpad.com). A standard two-way ANOVA, comparing CBZ administration (CBZ vs. vehicle) with drug (quinpirole vs. saline) was performed to compare arterial plasma radioactivity input functions, plasma unesterified fatty acid concentrations, brain eicosanoid concentrations and regional values of k* and J in using SPSS 11.0 (SPSS Inc., Chicago, IL, USA, http://www.spss.com). Where interactions between CBZ and quinpirole were statistically insignificant, probabilities of effects of CBZ and quinpirole were reported. Where interactions were statistically significant, these probabilities were not reported because they cannot be interpreted [51] . Instead, unpaired two-tailed t-tests were used to compare quinpirole and saline responses between CBZ-and vehicle-treated rats as well as saline responses in CBZ-compared with vehicle-treated rats. Other comparisons were not considered relevant. A post-hoc test was not used to avoid a correction for multiple comparisons. However, when a Bonferroni post-hoc test with correction for three comparisons was performed, statistical significance of differences were not changed. Data are reported as means ± SD, with statistical significance taken as P B 0.05.
Results
Physiology, Behavior and Arterial Plasma Radioactivity
At surgery, CBZ-treated rats had a lower mean body weight than vehicle-treated rats, 269 ± 11 g (n = 12) versus 281 ± 11 g (n = 12) (P = 0.02). Quinpirole (1 mg/kg) provoked behavioral cycles, each consisting of an ''activity'' period (repetitive sniffing, mouth and head-turning) followed by a ''calm'' period, whereas saline did not obviously affect behavior (Table 1) . No significant difference in mean cycling periods was observed in CBZ-treated compared to vehicle-treated rats (Table 1) . Compared with saline, quinpirole did not significantly affect arterial pH, pCO 2 or pO 2 , or blood pressure or heart rate ( Table 1) .
Following intravenous [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]AA infusion, neither CBZ nor quinpirole modified the integral of plasma radioactivity in the organic fraction, the input function for determining k* in Eq. 1. The mean integral, (nCi 9 s)/ml (n = 5-6), did not differ significantly between groups: vehicle plus saline, 213,888 ± 28,329; vehicle plus quinpirole, 253,791 ± 32,823; CBZ plus saline, 194,933 ± 15,343; CBZ plus quinpirole, 215,594 ± 14,957.
Plasma Concentrations of Unlabeled Unesterified Fatty Acids
A two-way ANOVA showed statistically insignificant interactions between CBZ and quinpirole with regard to eight of the measured plasma concentrations of Table 1 Effects of carbamazepine and quinpirole on physiological parameters Values are means ± SD (n = 6) measured before and 11 min after saline or quinpirole (1 mg/kg, i.v.) injection. None of these physiological parameters was statistically significantly affected by chronic carbamazepine or quinpirole administration unesterified fatty acids, including AA (Table 2) . Chronic CBZ compared with vehicle had a negative main effect on oleic, linoleic, a-linolenic and docosahexaenoic acid concentrations (Table 2 ). Quinpirole did not have a main effect on any concentration.
Regional Brain AA Incorporation Coefficients, k* Figure 1 presents coronal autoradiographs of brains from rats treated chronically with vehicle or CBZ, then injected acutely with either saline or quinpirole. It illustrates that quinpirole increased k* for AA in multiple brain regions in the vehicle-but not CBZ-pretreated rats. Data from such autoradiographs were collated and analyzed in Table 3 .
Quinpirole Administration in Vehicle-Treated Rats
Mean AA incorporation coefficients, k*, determined in each of 82 brain regions, were subjected to a two-way ANOVA (Table 3) . Statistically significant interactions between quinpirole and CBZ were found in 30 regions. In 29 of these, t-tests showed that quinpirole compared with saline significantly increased k* in the vehicle-treated rats. The regions, many of which belong to dopamine circuits [21] , include prefrontal layer IV (18%), frontal 10 and 8 (16-36%), anterior cingulate (16%), motor (21-44%), somatosensory (21-65%), auditory (19-23%) and visual layer IV cortical areas (20%), diagonal band ventral (19%), nucleus accumbens (38%), caudate-putamen (21-31%), medial septal nuclei (28%), 2 regions of the thalamus (11-27%), and the substantia nigra (22%). Quinpirole also significantly increased k* for AA in 6 regions having statistically insignificant CBZ 9 quinpirole interactions-lateral and medial habenular nuclei (12% and 9%, respectively), dorsal lateral geniculate nucleus (27%), ventroposterior thalamus nucleus lateral (14%), paratenial thalamus nucleus (24%), and olfactory tubercle (17%). In total, then, 35 brain regions were significantly activated by quinpirole in vehicle-treated control rats. The pattern of significant activations is illustrated in a sagittal representation of the brain in Fig. 2a .
Effects of Chronic CBZ Administration at Baseline
In the 30 regions in which CBZ 9 quinpirole interactions were statistically significant, t-tests showed that chronic ) are given on a color scale from 4 (blue) to 8 (yellow-orange). Abbreviations: Acb, nucleus accumbens; Acg, anterior cingulate cortex; CPu, caudate-putamen; DB, diagonal band; Fr 8, frontal cortex area 8; Fr 10, frontal cortex area 10; Mot, motor cortex. Note: For interpretation of the references to color in this figure legend, the reader is referred to the online version of this article CBZ did not significantly change mean baseline (acute saline) k* in any region. Where CBZ 9 quinpirole interactions were statistically insignificant, chronic CBZ reduced k* in 4 regions: visual cortex layer VI (-11%), hippocampus CA1 (-12%), lateral septal nucleus (-13%) and grey layer of the superior colliculus (-14%) ( Table 3 , Fig. 2b ).
Effects of Quinpirole in Chronic CBZ-Treated Rats
Of the 30 regions in which CBZ 9 quinpirole interactions were statistically significant, quinpirole compared with saline reduced k* in somatosensory cortex layer II-III (-15%) and auditory cortex layer IV (-12%) (Fig. 2c ). In the 6 regions in which CBZ 9 quinpirole interactions were statistically insignificant and in which quinpirole had a significant effect in vehicle-treated rats, chronic CBZ had a main effect by preventing the quinpirole-induced k* increments (Table 3) .
Regional Rates of Incorporation of Unlabeled Unesterified AA into Brain Baseline (following saline)-and quinpirole-induced regional values of J in were calculated by Eq. 2 (data not shown).
Because the mean plasma concentration of unlabeled unesterified AA did not differ significantly between chronic CBZ-and vehicle-treated rats (Table 2) , baseline differences and percent changes in J in corresponded to the differences and percent changes in respective values of k* (Table 3 ). In vehicle-treated rats, baseline values of J in ranged from 4.5 fmol/s/g in the internal capsule to 36.1 fmol/s/g in the choroid plexus. In CBZ-treated rats, no baseline value of J in differed significantly from its respective value in vehicle-treated rats; J in ranged from 3.9 fmol/s/g in the periventricular of the hypothalamus to CBZ Effect Saline (n = 5) Quinpirole (n = 6) Saline (n = 6) Quinpirole (n = 6) P-value P-value P-value Abbreviations: nu, nucleus; k* = (ml/s/g) 9 10
-4
. Each k* value is a mean ± SD Main effects are not reported if statistically significant CBZ 9 quinpirole interaction, when unpaired t-tests were performed. * P \ 0.05; ** P \ 0.01; *** P \ 0.001; Vehicle plus quinpirole versus vehicle plus saline, CBZ plus saline versus vehicle plus saline, and CBZ plus quinpirole versus CBZ plus saline Fig. 2 Difference patterns of k* responses to quinpirole and carbamazepine in sagittal representation of rat brain. Regions in which k* was increased significantly (P \ 0.05) compared with chronic vehicle + saline are solid black, regions in which k* was decreased significantly are hatched. List of regions: A, amygdala; Acb, nucleus accumbens; Aud, auditory cortex; av, anteroventral thalamic nucleus; CbG, cerebellar gray matter; CbW, cerebellar white matter; CPu, caudate putamen; DLG, dorsal lateral geniculate nucleus; Fr, frontal cortex; GP, globus pallidus; HB, habenular nuclei; HIP, hippocampus; HYP, hypothalamus; IC, inferior colliculus; IPC, interpeduncular nucleus; MM, mammillary nucleus; mG, medial geniculate nucleus; MolCBG, molecular layer of cerebellar gray matter; Mot, motor cortex; OT, olfactory tubercle; PF, prefrontal cortex; pt, paratenial thalamic nucleus; SN, substantia nigra; S, septum; SS, somatosensory cortex; SC, superior colliculus; SCgl, gray layer of superior colliculus; STH, subthalamic nucleus; THa, thalamus; Vis, visual cortex 30.9 fmol/s/g in the choroid plexus. As noted above, J in increments following quinpirole in the vehicle-treated rats did not differ significantly from respective increments the CBZ-treated rats (data not shown).
Brain PGE 2 and TXB 2 Concentrations
A two-way ANOVA demonstrated both significant and insignificant interactions between CBZ and quinpirole with regard to brain PGE 2 and TXB 2 ( Table 4) . Consequent t-tests showed that chronic CBZ decreased the basal PGE 2 concentration by 25% (P = 0.048). Acute quinpirole increased brain PGE 2 by 67% (P = 0.011) in vehicletreated rats, whereas chronic CBZ prevented this increase. CBZ and quinpirole had main effects on TXB 2 (Table 4) . Chronic CBZ decreased the basal TXB 2 concentration by 35%. Quinpirole reduced the TXB 2 concentration by 23% in vehicle-treated rats but had no effect in the CBZ-treated rats (Table 4) .
Discussion
Chronic administration of CBZ, sufficient to produce a plasma CBZ concentration therapeutically relevant to bipolar disorder, blocked the increments in k* for AA and in whole brain PGE 2 and TXB 2 concentrations that were produced in chronic vehicle-treated rats injected with quinpirole. Chronic CBZ by itself reduced k* in four regions as well as global brain concentrations of PGE 2 and TXB 2 .
The effects in rats of chronic CBZ on baseline brain AA cascade markers, and on quinpirole-induced changes in these markers, are comparable to those produced by chronic LiCl feeding [5] . For example, chronic LiCl like chronic CBZ blocked quinpirole-induced increments in k* for AA (we have not as yet examined lithium's ability to block the PGE 2 increment following quinpirole). Both chronic LiCl and CBZ reduced AA turnover in rat brain phospholipids, brain mRNA, protein and activity levels of cPLA 2 , and the DNA-binding capacity and protein level of a cPLA 2 transcription factor, activator protein-2 [11, 19, 27, 42, 43, 45] . These observations, plus clinical data that dopaminergic neurotransmission is disturbed in bipolar disorder [13, 28, 31] , and that dopamine receptor antagonists can be therapeutic whereas drugs that stimulate dopamine synthesis, bind to dopamine receptors or reduce dopamine reuptake often precipitate mania (see ''Introduction''), suggest that mood stabilizers are therapeutic in bipolar disorder in part by suppressing excessive D 2 -like receptor signaling involving AA.
CBZ could have downregulated the D 2 -like receptorinitiated AA signal by reducing synaptic dopamine release and synthesis, D 2 receptor density, D 2 -like coupled Ga o/i , D 2 -like receptor phosphorylation, or histone deacetylation by histone deacetylase [2, 14, 32, 34, 35, 38] . CBZ also could have altered G-protein receptor kinase translocation from cytosol to cell membrane, and thus densitiztion of D 2 -like receptors [24] . CBZ's ability to reduce rat brain cPLA 2 transcription and COX activity also could have contributed to the reduced signaling, associated with reduced basal PGE 2 and TXB 2 concentrations and reduced quinpirole-induced changes in these concentrations [8, 27] . PGE 2 and TXB 2 are converted preferentially from AA by COX-2 and COX-1, respectively. When these enzymes are pharmacologically inhibited or knocked out in rodent models, k* responses to drugs acting at cPLA 2 -coupled neuroreceptors are reduced or lost, as are the increments in brain PGE 2 and/or TXB 2 concentrations [9, 10] . Our finding that quinpirole elevated brain PGE 2 in vehicletreated rats agrees with prior in vitro and in vivo observations [23] . The mechanism for the reduction of brain TXB 2 by quinpirole is not apparent but might be elucidated by studying the drug effect on COX-1 and thromboxane synthase expression in brain.
The baseline values of k* for AA in vehicle-treated rats, which ranged from 2.65 to 20.9 9 10 -4 ml/s/g brain, are similar to previously reported values [5, 6, 8, 10, 15] . Quinpirole significantly increased k* in 35 regions, many of which belong to dopaminergic circuits containing D 2 receptors (e.g. caudate-putamen and substantia nigra) [33] , D 3 receptors (e.g. nucleus accumbens and olfactory tubercle) [50] or D 4 receptors (e.g. cerebral cortex) [55] . Giving selective D 2 , D 3 and D 4 agonists or antagonists might identify the contributions of the different receptor subtypes to the k* signal. Furthermore, regional baseline values of J in in vehicle-treated rats, 4.5-36.1 fmol/s/g, agree with a published global value of 6.57 fmol/s/g [11] . Given that J in represents the regional rate of metabolic AA loss from brain [10, 44] , our data on J in indicate comparable baseline rates of AA loss in vehicle-and CBZ-treated rats. Chronic CBZ, unlike chronic lithium [5, 12] did not prevent the quinpirole induced hyperactivity or stereotypy (Table 1) . Chronic CBZ or chronic valproate also do not affect quinpirole-induced locomotor activity [48] . As each of the three anti-bipolar agents downregulates the brain AA cascade, their different effects on quinpirole-induced behaviors suggest that these behaviors don't involve AA signaling and, moreover, that the quinpirole-induced activity cycles are not modeling bipolar disorder [48] .
In addition to attenuating D 2 -like receptor-mediated AA signaling, chronic lithium, CBZ and valproic acid [6] [7] [8] each attenuates AA signaling mediated by glutamatergic N-methyl-D-aspartate (NMDA) receptors in unanesthetized rats [6, 8] . As D 2 -like and NMDA receptors are often functionally coupled and co-localized on the same neurons in brain [52, 54] , these data suggest that mood stabilizers that are effective against mania suppress AA signaling coupled to both D 2 -like and NMDA receptors. In this regard lamotrigine, which is preferred for treating bipolar depression and rapid recycling, is considered to act in part by reducing presynaptic glutamate release [22] . A role for both receptor subtypes is consistent with evidence of disturbed dopaminergic and NMDA transmission in bipolar disorder [1, 13, 20, 28, 31, 36, 37, 40] .
It now is possible to measure k* for AA in the human brain with positron emission tomography following the intravenous injection of [1- 11 C]AA [25] . Thus, it would be of interest to see if our findings in rats can be extrapolated to bipolar disorder patients off and on treatment with mood stabilizers, by giving them dopamine receptor agonists to stimulate the AA signal, such as apomorphine or ropinerole [17, 30, 56] .
In conclusion, chronic CBZ blocked the increments in k* for AA as well in the global brain PGE 2 concentration seen in response to quinpirole in chronic-vehicle treated rats. Those and related observations regarding chronic lithium and valproic acid support the hypothesis that mood stabilizers of proven efficacy against bipolar disorder may act by downregulating brain AA signaling coupled to both D 2 -like and NMDA receptors.
